Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study

Abstract EN

This study examines survival time in patients with small bowel tumors and determines its contributing factors.

In this retrospective analytical study, the medical records of 106 patients with small bowel cancer (from 2006 to 2011) were investigated.

The patients’ data were extracted, including age, gender, clinical presentation, location of tumor, histological type, grade of tumor, site of metastasis, and type of treatment.

The Kaplan-Meier test was used to estimate the overall survival time and the Log-rank test to compare the survival curves.

The Cox regression was also used to evaluate the effect of the confounding variables on survival time.

This study was conducted on 106 patients with a median age of 60 years (Min: 7, Max: 87).

The tumor types included adenocarcinoma (n=78, 73.6%), MALToma (n=22, 20.8%), neuroendocrine tumors (n=4, 3.8%), and sarcoma (n=2.

1.8%).

Grade 3 adenocarcinomas had a significantly lower survival time (HR: 1.48, 95% CI: 0.46-2.86; P=.001).

Combined therapy (chemotherapy and surgery) vs.

single-therapy (only surgery) had no significant effects on the survival of the patients with MALToma (5 vs.

3 months, 95% CI: 1.89-5.26; P=.06).

There were no significant differences between the survival time in adenocarcinoma and MALToma (12 vs.

20 months, 95% CI: 6.24-24.76; P=.49).

Tumor grade was the only independent prognostic factor that affected survival in adenocarcinoma.

The patients diagnosed with MALToma in the study also had a poor prognosis, and the type of treatment had no significant effect on their survival.